Percutaneous Thermal Ablation in Lung Tumors

Condition(s) studied

Investigational drug(s) / intervention(s)

Percutaneous thermal ablation of lung tumors: Percutaneous radiofrequency ablation

Study summary

Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.

Eligibility

Primary outcome measure(s)

• Accuracy and success — 1 year
  Determination of tumor size in cm after thermal ablation in treatment of patients who are unfit for surgery or have tumors smaller than 5 cm or metastasis to the lung

Trial sites (1)

More Assiut University trials in Egypt

Other trials for the same condition